Almirall

(IN BRIEF) Almirall and Absci have expanded their AI-based drug discovery collaboration by selecting a second dermatological target, following the initial success of AI-designed antibody leads against a difficult-to-drug protein. Their partnership, active since November 2023, leverages Absci’s Integrated Drug … Read the full press release →

(IN BRIEF) Almirall’s new data highlights the alarming lack of awareness regarding actinic keratosis (AK), a common precancerous dermatological condition linked to sun exposure, with more than one-third of affected individuals unaware of its causes. The survey, conducted across Spain, … Read the full press release →

(IN BRIEF) A recent study conducted by researchers from the Universities of Bristol and Bath, King’s College London, and University Medical Center Utrecht highlights the concerning prevalence of repeat antibiotic prescriptions for respiratory tract infections (RTIs) within the same episode … Read the full press release →

(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release →

(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release →

(IN BRIEF) Almirall S.A., a global pharmaceutical company specializing in medical dermatology, has confirmed its involvement in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place from January 8th to 11th, 2024. Carlos Gallardo, Chairman and CEO … Read the full press release →

(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, have entered into a license agreement to develop bispecific antibodies for up to three undisclosed target pairs. Almirall … Read the full press release →

(IN BRIEF) Almirall, a global biopharmaceutical company specializing in medical dermatology, has entered into an agreement with Centrient Pharmaceuticals, a leader in sustainable biosynthetic pharmaceuticals, to establish a dedicated innovation lab at Almirall’s R&D center in Sant Feliu de Llobregat, … Read the full press release →

Durch diese Lizenzvereinbarung mit Ablexis erhält Almirall Rechte zur Nutzung der AlivaMab®-Maustechnologie für die Forschung, Entwicklung und Vermarktung von Antikörpern AlivaMab Mouse bietet hochmoderne transgene Mausplattformen, die humane therapeutische Antikörper mit hoher Vielfalt liefern Almirall wird mit AlivaMab Discovery Services … Read the full press release →

Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release →

Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release →

These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release →

The Industry Committee is formed, among others, by Airbus, Almirall, Alstom España, Inditex, Indra, Mercadona, Renault España and Técnicas Reunidas. The Ministries of Industry, of Economy and of Competitiveness also participate.. At its inaugural meeting, the Commission advocates a State … Read the full press release →

Both parties have reached a negotiated solution given the situation of the pharmaceutical market and the moment that the company is facing in Spain.  Barcelona, Spain, 5-2-2014 — /EuropaWire/ — Almirall and the representatives of the employees have signed an agreement which … Read the full press release →

Most of the 64 million COPD patients around the world, including over 2 million in Spain, must contend with breathlessness, excessive mucus, chronic cough and other debilitating symptoms throughout  24hours a day The World Health Organization estimates that COPD kills … Read the full press release →

Barcelona,  05-8-2013 — /EuropaWire/ — Almirall’s H1: Executing on growth platforms, financial delivery on track Financial performance in line with guidance Aclidinium now available in 13 countries with five new launches planned before year’s end US/EU filings of aclidinium/formoterol combination are … Read the full press release →

The NAR and the 9th symposium on respiratory diseases reflect Almirall’s commitment to patients and its support and training for professionals Aclidinium, Almirall’s proprietary R&D medicine for the relief of Chronic Obstructive Pulmonary Disease (COPD) symptoms through its user-friendly delivery … Read the full press release →